ResearcherJohns Hopkins UniversityActive in the last 2 years
Heng‐Chung Kung
Matched on ORCID iD 0000-0002-9330-0971; OpenAlex author ID A5016962917. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 21
2023: 3 papers · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper
Papers 7
- Complement-secreting CAFs are associated with better prognosis in pancreatic cancer: single-cell multiomics. Co-author DOI 10.1136/gutjnl-2025-335683↗
- The tumour microenvironment in pancreatic cancer - new clinical challenges, but more opportunities. Co-author DOI 10.1038/s41571-025-01077-z↗
- Distinct response to IL-1β blockade in liver- and lung-specific metastasis mouse models of pancreatic cancer with heterogeneous tumor microenvironments. First author DOI 10.1186/s40164-025-00607-w↗
- Targeting heterogeneous tumor microenvironments in pancreatic cancer mouse models of metastasis by TGF-β depletion. First author DOI 10.1172/jci.insight.182766↗
- Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study. Co-author DOI 10.1002/mco2.216↗
- Engineered TCR T-cell therapy targeting mass spectrometry-identified natural epitope in PDAC. Co-author DOI 10.1016/j.canlet.2023.216366↗
- DNA damage repair mutations in pancreatic cancer- prognostic or predictive? Co-author DOI 10.3389/fonc.2023.1267577↗
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jun Yu · 3 shared papers, 2023 · strength 0.77
- Paper Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study. DOI 10.1002/mco2.216↗
- Paper DNA damage repair mutations in pancreatic cancer- prognostic or predictive? DOI 10.3389/fonc.2023.1267577↗
- Paper Engineered TCR T-cell therapy targeting mass spectrometry-identified natural epitope in PDAC. DOI 10.1016/j.canlet.2023.216366↗
- Lei Zheng · 3 shared papers, 2023–2025 · strength 0.76
- Paper The tumour microenvironment in pancreatic cancer - new clinical challenges, but more opportunities. DOI 10.1038/s41571-025-01077-z↗
- Paper Distinct response to IL-1β blockade in liver- and lung-specific metastasis mouse models of pancreatic cancer with heter… DOI 10.1186/s40164-025-00607-w↗
- Paper Engineered TCR T-cell therapy targeting mass spectrometry-identified natural epitope in PDAC. DOI 10.1016/j.canlet.2023.216366↗
- Jacquelyn W. Zimmerman · 2 shared papers, 2025–2026 · strength 0.63
- Sophia Y. Chen · 3 shared papers, 2023–2025 · strength 0.58
- Paper Distinct response to IL-1β blockade in liver- and lung-specific metastasis mouse models of pancreatic cancer with heter… DOI 10.1186/s40164-025-00607-w↗
- Paper Targeting heterogeneous tumor microenvironments in pancreatic cancer mouse models of metastasis by TGF-β depletion. DOI 10.1172/jci.insight.182766↗
- Paper Engineered TCR T-cell therapy targeting mass spectrometry-identified natural epitope in PDAC. DOI 10.1016/j.canlet.2023.216366↗
- William R. Burns · 2 shared papers, 2024–2025 · strength 0.41
- Paper Distinct response to IL-1β blockade in liver- and lung-specific metastasis mouse models of pancreatic cancer with heter… DOI 10.1186/s40164-025-00607-w↗
- Paper Targeting heterogeneous tumor microenvironments in pancreatic cancer mouse models of metastasis by TGF-β depletion. DOI 10.1172/jci.insight.182766↗
- Jianxin Wang · 2 shared papers, 2023–2024 · strength 0.35
- Robert A. Anders · 1 shared paper, 2026 · strength 0.26
- Yongsu Ma · 1 shared paper, 2026 · strength 0.26
- Kai Chen · 1 shared paper, 2026 · strength 0.26
- Pengfei Wu · 1 shared paper, 2026 · strength 0.26
- Yinmo Yang · 1 shared paper, 2026 · strength 0.26
- Xiaodong Tian · 1 shared paper, 2026 · strength 0.26
- Kaiyi Mu · 1 shared paper, 2025 · strength 0.23
- Tian‐Run Lv · 1 shared paper, 2023 · strength 0.22
- Ya-Fei Hu · 1 shared paper, 2023 · strength 0.22
- Fu‐Yu Li · 1 shared paper, 2023 · strength 0.22
- Hai‐Jie Hu · 1 shared paper, 2023 · strength 0.22
- William L. Hwang · 1 shared paper, 2024 · strength 0.18
- Lei Zheng · 1 shared paper, 2024 · strength 0.18
- Kenji Fujiwara · 1 shared paper, 2023 · strength 0.17
- Tengyi Zhang · 1 shared paper, 2023 · strength 0.17
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.